[1] CINAROGLU S, BASER O.The relationship between medical innovation and health expenditure before and after health reform[J].Health Policy and Technology,2018,7(4):379-387.[2] DIMASI J A, GRABOWSKI H G, HANSEN R W.Innovationinthe pharmaceutical industry:new estimates of R&D costs[J].Journal of Health Economics, 2016，47(5):20-33.[3] SZCZYGIELSKI K, GRABOWSKI W, PAMUKCU M T, et al.Does government support for private innovation matter:firm-level evidence from two catching-up countries[J].Research Policy, 2017, 46(1):219-237.[4] WANG J.Innovation and government intervention:a comparison of Singapore and Hong Kong[J].Research Policy, 2018, 47(2):399-412.[5] BARDEY D, BOMMIER A, JULLIEN B.Retail price regulation and innovation:reference pricing in the pharmaceutical industry[J].Journal of Health Economics, 2010, 29(2):303-316.[6] COSTA-FONT J, MCGUIRE A, VAROL N.Price regulation and relative delays in generic drug adoption[J].Journal of Health Economics, 2014, 38(12):1-9.[7] LEVAGGI, ROSELLA.Pricing schemes for new drugs:a welfare analysis[J].Social Science & Medicine, 2014, 102(2):69-73.[8] GROSSMANN, VOLKER.Do cost-sharing and entry deregulation curb pharmaceutical innovation[J].Journal of Health Economics, 2013, 32(5):881-894.[9] BLUME-KOHOUT M E, SOOD N.Market size and innovation:effects of medicare part D on pharmaceutical research and development[J].Journal of Public Economics, 2013, 97(1):327-336.[10] FREEDMAN S, LIN H, SIMON K.Public health insurance expansions and hospital technology adoption[J].Journal of Public Economics, 2015, 121(1):117-131.[11] KALCHEVA I, MCLEMORE P, PANT S.Innovation:the interplay between demand-side shock and supply-side environment[J].Research Policy,2018,47(1):440-461.[12] 李晓宏,孙林岩,何哲.中国技术进步影响因素研究(1981-2006年)——基于向量自回归模型实证分析[J].软科学,2008(7):24-29.[13] 杨亭亭,罗连化,许伯桐.政府补贴的技术创新效应:“量变”还是“质变”[J].中国软科学,2018(10):57-66.[14] 刘红霞,幸丽霞,田学浩.上市公司补亏政策变化及其经济后果研究——基于资本公积金补亏禁令的视角[J].财政研究,2017(12):91-100.[15] 韩永辉,黄亮雄,王贤彬.产业政策推动地方产业结构升级了吗——基于发展型地方政府的理论解释与实证检验[J].经济研究,2017(8):35-50.[16] 钱雪松,康瑾,唐英伦，等.产业政策、资本配置效率与企业全要素生产率——基于中国2009年十大产业振兴规划自然实验的经验研究[J].中国工业经济,2018(8):44-61.[17] 夏怡然,陆铭.跨越世纪的城市人力资本足迹——历史遗产、政策冲击和劳动力流动[J].经济研究,2019（1）：132-149.[18] MCKAY N L.The prisoner's dilemma:an obstacle to cooperation in health care markets[J].Medical Care Review, 1994, 51(2):179.[19] CALEM P S, RIZZO J A.Competition and specialization in the hospital industry:an application of hotelling'slocation model[J].Southern Economic Journal, 1995, 61(4):1182-1198.[20] KANE N M, MANOUKIAN P D.The effect of the medicareprospective payment system on the adoption of new technology.thecase of cochlear implants[J].New EnglandJournal ofMedicine, 1990, 321(20):1322-1323.[21] WEISBROD B A.The health care quadrilemma:an essay on technological change, insurance, quality of care, and cost containment[J].Journal of Economic Literature, 1991, 29(2):523-552.[22] FANG H.Insurance markets for the elderly[M].New York:Handbook of the Economics of Population Aging, 2016.[23] ADAIR, ALETHEA, HYDELAY, et al.Health care technology and its assessment in eight countries[M].Office of Technology Assessment, 1995.[24] BRADLEY R.Growth of U.S.health care spending[J].Contemporary Economic Policy, 2010, 12(4):45-56.[25] HERRING B, TRISH E.Explaining the growth in U.S.health care spending using state-level variation in income, insurance, and provider market dynamics[J].Inquiry, 2015, 52(12):1-11.[26] HARTMAN M, MARTIN A B, ESPINOSA N, et al.National health care spending in 2016:spending and enrollment growth slow after initial coverage expansions[J].Health Affair, 2017, 37(1):150-160.[27] SHEINER,LOUISE.Perspectives on health care spending growth[J].Hutchins Center Working Paper,2014.[28] BROWN L D.Common sense meets implementation:certificate-of-need regulation in the states[J].Journal of Health Political Policy Law, 1983, 8(3):480-494.[29] HILLMAN B J.Physicians' acquisition and use of new technology in an era of economic constraints[R].Technology & Health Care in An Era of Limits, 1992.
